Table 2. Incidence of genomic aberrations analyzed by SALSA MLPA P335-B1 ALL-IKZF1.
| Non-ERG-related | ERG-related | ERG-related without ERG deletion | ERG-related with ERG deletion | |||||
|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | N | % | |
| Total n. of patients | 108 | 35 | 20 | 14 | ||||
| IKZF1 | ||||||||
| Not deleted | 45 | 73.8 | 22 | 64.7 | 14 | 73.7 | 7 | 50.0 |
| Deleted | 16 | 26.2 | 12 | 35.3 | 5 | 26.3 | 7 | 50.0 |
| Not known | 47 | 1 | 1 | 0 | ||||
| p-value (NK excluded)=0.35 | ||||||||
| P2RY8-CRLF2 | ||||||||
| Not deleted | 52 | 85.2 | 32 | 94.1 | 18 | 94.7 | 13 | 92.9 |
| Deleted | 9 | 14.8 | 2 | 5.9 | 1 | 5.3 | 1 | 7.1 |
| Not known | 47 | 1 | 1 | 0 | ||||
| p-value (NK excluded)=0.32 | ||||||||
| CDKN2A/B | ||||||||
| Not deleted | 31 | 50.8 | 29 | 85.3 | 14 | 73.7 | 14 | 100.0 |
| Deleted | 30 | 49.2 | 5 | 14.7 | 5 | 26.3 | 0 | |
| Not known | 47 | 1 | 1 | 0 | ||||
| p-value (NK excluded)<0.001 | ||||||||
| PAX5 | ||||||||
| Not deleted | 32 | 52.6 | 30 | 88.2 | 16 | 84.2 | 13 | 92.9 |
| Deleted | 29 | 47.4 | 4 | 11.8 | 3 | 15.8 | 1 | 7.1 |
| Not known | 47 | 1 | 1 | 0 | ||||
| p-value (NK excluded)<0.001 | ||||||||
| ETV6 | ||||||||
| Not deleted | 50 | 82.0 | 31 | 91.2 | 16 | 84.2 | 14 | 100.0 |
| Deleted | 11 | 18.0 | 3 | 8.8 | 3 | 15.8 | 0 | |
| Not known | 47 | 1 | 1 | 0 | ||||
| p-value (NK excluded)=0.37 | ||||||||
| BTG1 | ||||||||
| Not deleted | 55 | 90.2 | 33 | 97.1 | 19 | 100.0 | 13 | 92.9 |
| Deleted | 6 | 9.8 | 1 | 2.9 | 0 | 1 | 7.1 | |
| Not known | 47 | 1 | 1 | 0 | ||||
| p-value (NK excluded)=0.42 | ||||||||
| RB1 | ||||||||
| Not deleted | 55 | 90.2 | 32 | 94.1 | 17 | 89.5 | 14 | 100.0 |
| Deleted | 6 | 9.8 | 2 | 5.9 | 2 | 10.5 | 0 | |
| NK | 47 | 1 | 1 | 0 | ||||
| p-value (NK excluded)=0.71 | ||||||||
| EBF1 | ||||||||
| Not deleted | 56 | 91.8 | 34 | 100.0 | 19 | 100.0 | 14 | 100.0 |
| Deleted | 5 | 8.2 | 0 | 0 | 0 | |||
| Not known | 47 | 1 | 1 | 0 | ||||
| p-value (NK excluded)=0.16 | ||||||||
To the left, incidence of aberrations in 95/143 patients in the B-others cohort according to the distinction in unsupervised gene expression analyses: ERG-related (34/35), non-ERG-related (61/108). To the right, incidence of aberrations in 33 out of 34 ERG-related patients according to the presence of ERG intragenic deletion (one ERG-related patients not analyzed for the ERG intragenic deletion was excluded). Clinical parameters were not evaluated by statistical tests because of low patients numerosity.